Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Advanced, anaplastic lymphoma kinase (ALK)-positive lung cancer is currently treated with the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK inhibitors (e.g., ceritinib, alectinib) upon progression. Second-generation inhibitors are generally effective even i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Gainor, Justin F., Dardaei, Leila, Yoda, Satoshi, Friboulet, Luc, Leshchiner, Ignaty, Katayama, Ryohei, Dagogo-Jack, Ibiayi, Gadgeel, Shirish, Schultz, Katherine, Singh, Manrose, Chin, Emily, Parks, Melissa, Lee, Dana, DiCecca, Richard H., Lockerman, Elizabeth, Huynh, Tiffany, Logan, Jennifer, Ritterhouse, Lauren L., Le, Long P., Muniappan, Ashok, Digumarthy, Subba, Channick, Colleen, Keyes, Colleen, Getz, Gad, Dias-Santagata, Dora, Heist, Rebecca S., Lennerz, Jochen, Sequist, Lecia V., Benes, Cyril H., Iafrate, A. John, Mino-Kenudson, Mari, Engelman, Jeffrey A., Shaw, Alice T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050111/
https://ncbi.nlm.nih.gov/pubmed/27432227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0596
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados